Biosimilars: Is Small Dip In Development Indicative Of Sustained Downward Trend?
Executive Summary
As US FDA sees dip in application development, experts offer contrasting assessments about future of biosimilars at AAM's GRx Biosims conference.
You may also be interested in...
VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
Momenta Is Exiting Biosimilars; Is That A Bellwether For Biosimilar Sentiment?
CEO Craig Wheeler talked to Scrip about the challenging biosimilar market dynamics and the company's decision to end most biosimilar drug development. The path to value creation in biosimilars is not clear, he said.